Oppenheimer Asset Management Inc. trimmed its position in Heska Corp (NASDAQ:HSKA) by 18.6% during the 3rd quarter, HoldingsChannel.com reports. The fund owned 4,128 shares of the medical research company’s stock after selling 943 shares during the period. Oppenheimer Asset Management Inc.’s holdings in Heska were worth $468,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in HSKA. Dimensional Fund Advisors LP increased its position in shares of Heska by 4.7% in the 1st quarter. Dimensional Fund Advisors LP now owns 191,044 shares of the medical research company’s stock valued at $15,106,000 after acquiring an additional 8,513 shares during the period. Millennium Management LLC increased its position in shares of Heska by 715.5% in the 1st quarter. Millennium Management LLC now owns 29,357 shares of the medical research company’s stock valued at $2,321,000 after acquiring an additional 25,757 shares during the period. Principal Financial Group Inc. increased its position in shares of Heska by 2.4% in the 1st quarter. Principal Financial Group Inc. now owns 49,975 shares of the medical research company’s stock valued at $3,952,000 after acquiring an additional 1,162 shares during the period. Raymond James Trust N.A. acquired a new position in shares of Heska in the 2nd quarter valued at $240,000. Finally, Summit Creek Advisors LLC increased its position in shares of Heska by 14.2% in the 2nd quarter. Summit Creek Advisors LLC now owns 71,868 shares of the medical research company’s stock valued at $7,459,000 after acquiring an additional 8,915 shares during the period. 88.63% of the stock is currently owned by hedge funds and other institutional investors.

HSKA has been the topic of several recent research reports. BidaskClub raised shares of Heska from a “sell” rating to a “hold” rating in a report on Thursday, October 18th. Zacks Investment Research lowered shares of Heska from a “hold” rating to a “sell” rating in a report on Thursday, August 9th. Benchmark initiated coverage on shares of Heska in a report on Thursday, July 19th. They issued a “buy” rating and a $120.00 price target on the stock. ValuEngine lowered shares of Heska from a “buy” rating to a “hold” rating in a report on Monday, July 30th. Finally, TheStreet lowered shares of Heska from a “b” rating to a “c+” rating in a report on Monday, August 20th. One investment analyst has rated the stock with a sell rating, three have given a hold rating and five have assigned a buy rating to the company. The company presently has an average rating of “Hold” and an average target price of $107.50.

In related news, EVP Rod Lippincott sold 2,805 shares of the firm’s stock in a transaction dated Friday, August 24th. The shares were sold at an average price of $104.01, for a total value of $291,748.05. Following the transaction, the executive vice president now directly owns 11,078 shares of the company’s stock, valued at approximately $1,152,222.78. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, COO Jason A. Napolitano sold 1,250 shares of the firm’s stock in a transaction dated Friday, September 28th. The shares were sold at an average price of $113.00, for a total transaction of $141,250.00. The disclosure for this sale can be found here. Over the last three months, insiders have sold 57,828 shares of company stock worth $5,854,060. Corporate insiders own 14.70% of the company’s stock.

HSKA stock opened at $100.26 on Thursday. Heska Corp has a 52-week low of $56.59 and a 52-week high of $114.50. The stock has a market cap of $756.30 million, a PE ratio of 48.43 and a beta of 0.73.

Heska (NASDAQ:HSKA) last posted its earnings results on Tuesday, November 6th. The medical research company reported $0.46 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.35 by $0.11. Heska had a net margin of 1.01% and a return on equity of 11.48%. The business had revenue of $30.96 million for the quarter, compared to analyst estimates of $31.14 million. As a group, research analysts predict that Heska Corp will post 1.67 earnings per share for the current year.

WARNING: “Oppenheimer Asset Management Inc. Cuts Position in Heska Corp (HSKA)” was first published by Daily Political and is the property of of Daily Political. If you are viewing this news story on another site, it was stolen and reposted in violation of international trademark & copyright law. The original version of this news story can be read at https://www.dailypolitical.com/2018/11/08/oppenheimer-asset-management-inc-cuts-position-in-heska-corp-hska.html.

About Heska

Heska Corporation manufactures, sells, and markets veterinary diagnostic and specialty products for canine and feline healthcare markets in the United States, Canada, Europe, and internationally. The company's Core Companion Animal Health segment offers Element DC and DRI-CHEM 7000 veterinary chemistry analyzers for blood chemistry and electrolyte analysis; HT5 and HEMATRUE veterinary hematology analyzers to measure blood cell and platelet count, and hemoglobin levels; Element POC blood gas and electrolyte analyzers; COAG veterinary analyzers; Element i immunodiagnostic analyzers; and IV infusion pumps.

Recommended Story: Outstanding Shares and The Effect on Share Price

Want to see what other hedge funds are holding HSKA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Heska Corp (NASDAQ:HSKA).

Institutional Ownership by Quarter for Heska (NASDAQ:HSKA)

Receive News & Ratings for Heska Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heska and related companies with MarketBeat.com's FREE daily email newsletter.